Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
CC transcript
|
|
PALISADE BIO, INC. (CUR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/09/2023 |
8-K
| Director compensation was amended/approved|
Docs:
|
"Palisade Bio, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: February 9, 2021 Approved by the Stockholders: April 9, 2021 Amended by the Stockholders: November 18, 2021 Amended by the Stockholders: June 8, 2023 1. General. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. Available Awards. The Plan provides for the grant of the following Awards: Incentive Stock Options; Nonstatutory Stock Options; SARs; Restricted Stock Awa...",
"Palisade Bio, Inc. 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: February 9, 2021 Approved by the Stockholders: April 9, 2021 Amended by the Stockholders: June 8, 2023 1. General; Purpose. The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends the 423 Component to qualify ..." |
|
| 04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _________________ Initial Exercise Date: April 5, 2023 Issue Date: April 5, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise def...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _________________ Initial Exercise Date: April 5, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and on or prior to 5:00 p.m. on April 5, 2028 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set forth ...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: 136,363 Initial Exercise Date: April 5, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, Ladenburg Thalmann & Co. Inc. or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 5, 2023 and on or prior to 5:00 p.m. on April 3, 2028 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to 136,363 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant to that certain Placement Agency Agreement, b...",
"Fax (805) 553-9783",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of April 3, 2023, between Palisade Bio, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Registered Shares and Registered Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Unregistered Shares and Unregistered Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as ...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"PLACEMENT AGENCY AGREEMENT _________, 2023 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019",
"Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules" |
|
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/08/2023 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 Issue Date: December ____, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 Issue Date: December ____, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: _______ Initial Exercise Date: ___________, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and on or prior to 5:00 p.m. on December ___, 2027 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set fo...",
"COMMON STOCK PURCHASE WARRANT palisade bio, inc. Warrant Shares: ______________ Initial Exercise Date: _______________, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2022 and on or prior to 5:00 p.m. on December ___, 2027 but not thereafter, to subscribe for and purchase from Palisade Bio, Inc., a Delaware corporation , up to 63,157 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the mean...",
"Legal Opinion of Silvestre Law Group, P.C",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December 30, 2022, between Palisade Bio, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and Registered Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW,...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"PLACEMENT AGENCY AGREEMENT Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019",
"Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules",
"Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules" |
|
| 12/16/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 10/17/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release is entered into between Thomas Hallam , Leading Biosciences, Inc. and Palisade Bio, Inc. . Whereas, pursuant to the Agreement and Plan of Merger , dated as of December 16, 2020, by and among the Company , LBS and Townsgate Acquisition Sub 1, Inc., a wholly owned subsidiary of the Company , the Company completed the previously announced merger transaction with LBS , pursuant to which LBS became a wholly owned subsidiary of the Company. Pursuant the Merger, Executive, who was the CEO of LBS and a member of the board of directors of LBS retained those positions and also became the CEO and a member of the board of directors of the Company. Whereas, effective October 11, 2022 , Executive has resigned from any and all positio...",
"Palisade Bio Announces Executive Leadership Transition" |
|
| 10/07/2022 |
8-K
| Quarterly results |
| 09/26/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 09/15/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs... |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Common Stock Purchase Warrant",
"Form of Securities Purchase Agreement, by and among the Company and the purchasers named therein",
"Palisade Bio Announces $2.0 Million Registered Direct Offering CARLSBAD, C.A., May 6, 2022 - Palisade Bio, Inc. , a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering. The closings of the sale of the securities in the financing is expected to occur on or about May 10, 2022, subject to the satisfaction of customary closing conditions. Palisade Bio intends to use the net proceeds from the fi..." |
|
| 05/03/2022 |
8-K
| Investor presentation |
| 04/20/2022 |
8-K
| Other Events Interactive Data |
| 03/16/2022 |
8-K
| Investor presentation |
| 02/24/2022 |
8-K
| Quarterly results |
| 02/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"WAIVER AND AMENDMENT AGREEMENT WAIVER AND AMENDMENT AGREEMENT , dated as of January 31, 2022 by and among Palisade Bio, Inc., previously known as "Seneca Biopharma, Inc.", a Delaware corporation, with headquarters at 5800 Armada Drive, Suite 210, Carlsbad, California 92008) , and the investor listed on Schedule I attached hereto . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Warrants , as applicable. WHEREAS: A. In connection with the Securities Purchase Agreement by and among Leading BioSciences, Inc., a Delaware corporation , PALI and the Holder, dated as of December 16, 2020, Private Company issued to the Holder shares of Private Company's Series 1 Preferred Stock and PALI issued to the Holder warrants, in the...",
"PALISADE BIO, INC. Warrant To Purchase Common Stock Warrant No.: J-02 Number of Shares of Common Stock: 2,250,000 Date of Issuance: January 31, 2022 Palisade Bio, Inc., a Delaware corporation , hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Altium Growth Fund, LP, the registered holder hereof or its permitted assigns , is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price then in effect, at any time or times on or after July 31, 2022 , but not after 11:59 p.m., New York time, on the Expiration Date, , 2,250,000 fully paid nonassessable shares of Common Stock, subject to adjustment as provided herein . Except as otherwise defined herein, capitalized terms in this Warra..." |
|
| 10/28/2021 |
8-K
| Investor presentation |
| 10/22/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/13/2021 |
8-K
| Quarterly results |
| 08/24/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 07/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 07/13/2021 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Registered Independent Public Accounting Firm",
"Condensed financial statements of Leading Biosciences, Inc., as of March 31, 2021 (unaudited) and December 31, 2020, and for the three months ended March 31, 2021 and 2020 (unaudited)",
"Unaudited pro forma condensed combined balance sheet as of March 31, 2021, the unaudited pro forma condensed combined statement of operations and comprehensive loss for the three months ended March 31, 2021 and the unaudited pro forma condensed combined statement of operations and comprehensive loss for the year ended December 31, 2020" |
|
| 07/09/2021 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 06/16/2021 |
8-K
| Other Events |
| 06/01/2021 |
8-K
| Quarterly results |
|
|
|